Sarah Kathryn Rouan - Jan 19, 2024 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Director
Signature
/s/ Michael Morneau as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Jan 19, 2024
Transactions value $
-$441,900
Form type
4
Date filed
1/19/2024, 08:35 PM
Previous filing
Jan 4, 2024
Next filing
Feb 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Options Exercise $250K +30K $8.32 30K Jan 19, 2024 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Sale -$692K -30K -100% $23.05 0 Jan 19, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VKTX Stock Option (Right to Buy) Options Exercise $0 -30K -54.55% $0.00 25K Jan 19, 2024 Common Stock 30K $8.32 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 3, 2023.